Leishmaniasis: cross-border specialty drug access for international patients

Quick orientation

Leishmaniasis affects an estimated 700,000 to 1 million new cases globally each year (WHO). Visceral, cutaneous, and mucocutaneous forms differ in severity and geography.

Typical age of onset. Any age; visceral leishmaniasis carries the highest mortality risk in children and immunocompromised patients.

Severity tiers. Severity ranges from self-limited cutaneous lesions to life-threatening visceral disease.

Why specialty drugs for Leishmaniasis are hard to access internationally

Treatment for leishmaniasis is highly regional. Liposomal amphotericin B is widely used for visceral disease; miltefosine is the only oral option but supply is intermittent in many endemic regions. Cross-border supply is sometimes the only path to treatment continuity.

Treatments approved by the FDA

• Impavido (miltefosine) — FDA approval: 2014. Mechanism: Oral antileishmanial alkylphosphocholine. Route: Oral once or twice daily for 28 days. US WAC ballpark: Approximately USD 5,000 to 12,000 per course. Country pricing: UAE · India · Egypt · Bahrain · Oman.
• Liposomal amphotericin B — FDA approval: Various, FDA approved. Mechanism: Polyene antifungal active against Leishmania. Route: Intravenous infusion. US WAC ballpark: Approximately USD 1,500 to 4,000 per vial.

Cross-border pathways used for Leishmaniasis

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Personal Import Scheme
• FDA Personal Use Import
• Cross-border Prescription

What your physician needs to know

• Confirm species and clinical form (visceral, cutaneous, mucocutaneous).
• Document HIV co-infection status where relevant.
• Miltefosine is teratogenic; pregnancy prevention is required.
• Coordinate with tropical medicine or infectious disease specialist.
• Some destination countries operate national programs that affect import permissions.

Common questions

Is miltefosine available in my country?

Availability is regional. Some endemic countries have national programs; supply outside these programs is intermittent.

How long is treatment?

Typically 28 days for miltefosine in visceral disease.

Are there alternatives?

Liposomal amphotericin B, paromomycin, and pentavalent antimonials are alternatives depending on species and clinical form.

What documents are required?

Infectious disease specialist's prescription, parasitologic confirmation, and clinical summary.

How fast can shipment occur?

Five to fifteen business days; faster for urgent cases where documentation permits.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Leishmaniasis, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Leishmaniasis

Reserved for you.